FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Submission of Matters to a Vote of Security Holders

FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of Matters to a Vote of Security
Holders.

At the Companys 2017 annual meeting of stockholders held on
June7, 2017, the stockholders voted on the four proposals listed
below. The proposals are described in detail in the Companys
definitive proxy statement for the 2017 annual meeting, filed
with the Securities and Exchange Commission on April24, 2017.The
results of the matters voted upon at the meeting were:

(a) All of the Class III nominees of the Board were elected to
hold office until the Companys 2020 annual meeting of
stockholders. The nominees were: (i)Thomas F. Kearns Jr:
37,733,019 shares of Common Stock voted for, 2,056,980
withheld, and 12,427,475 broker non-votes; (ii)Kalevi
Kurkijrvi, Ph.D.: 38,174,142 shares of Common Stock voted
for, 1,615,857 withheld, and 12,427,475 broker non-votes; and
(iii)Toshinari Tamura, Ph.D.: 38,163,332 shares of Common
Stock voted for, 1,626,667 withheld, and 12,427,475 broker
non-votes.

The term of office of directors Thomas B. Neff, Jeffrey W.
Henderson and James A. Schoeneck continues until the Companys
2018 annual meeting of stockholders. The term of office of
directors Jeffrey L. Edwards, Rory B. Riggs, Roberto Pedro
Rosenkranz, Ph.D., M.B.A., and Jorma Routti, Ph.D. continues
until the Companys 2019 annual meeting of stockholders.

(b) The stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers, as
disclosed in the 2017 definitive proxy statement:39,123,794
shares of Common Stock voted for, 536,281 against, and
129,924 abstaining.
(c) The stockholders approved of holding a vote, on an advisory
basis, on the compensation of the Companys named executive
officers Every Year:35,409,271 shares of Common Stock voted
for Every Year, 235,727 voted for Every Two Years, 4,092,531
voted for Every Three Years, and 52,470 abstaining.
(d) The stockholders ratified the selection by the Audit
Committee of the Board of PricewaterhouseCoopers LLP as the
independent registered public accounting firm of the Company
for its year ending December31, 2017: 52,118,719 shares of
Common Stock voted for, 67,829 against, and 30,926
abstaining.


About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

An ad to help with our costs